Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OlsAro has developed proprietary non-GMO salt-tolerant wheat lines that have shown an average of up to a 52% higher yield on saline soils compared to local controls over three years of field trials. Additional programs are ongoing for heat/drought/nitrogen traits. Commercial contracts are signed with a Bangladeshi seed company; regulatory approval processes are underway.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on OlsAro.